

DAFTAR PUSTAKA

- Abdel-Misih, S.R.Z., Bloomston, M. 2010. Liver Anatomy. *Surgical Clinics of North America*. 90 (2010) 643–653. doi:10.1016/j.suc.2010.04.017
- Alianto, R. 2015. Gambaran Histopatologi Karsinoma Hepatoseluler. *Cermin Dunia Kedokteran*. 229/ vol. 42 no. 6, th. 2015. Pp440-4.
- Arslanoglu, A., Seyal, A.R., Sodagari, F., Sahin, A., Miller, F.H., Salem, R., Yaghmai, V. 2016. Current Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review. *American Journal of Roentgonology*. 2016; 207:W1–W11. DOI:10.2214/AJR.15.15490
- Beaudart, C., McCloskey, E., Bruyère, O., Cesari, M., Rolland, Y., Rizzoli, R. 2016. Sarcopenia in daily practice: assessment and management. *BMC Geriatrics*. (2016) 16:170. DOI 10.1186/s12877-016-0349-4
- Begini, P., Gigante, E., Antonelli, G., Carbonetti, F., Iannicelli, E., Anania, G., *et al.* 2016. Sarcopenia Predicts Reduced Survival in Patients with Hepatocellular Carcinoma at First Diagnosis. *Annals of hepatology*. 2017; 16 (1): 107-114. DOI : 10.5604/16652681.1226821.
- Budiarta, I.G.A.I.M., Aryana, A.G.P.S., Purnami, N.K.R., Putrawan, I.B., Astika, I.N., Kuswardhani, R.A.T. 2019. Hubungan massa otot pada sarkopenia dengan status fungsional lanjut usia di Desa Pendawa, Kabupaten Buleleng, Bali. *Udayana J of Interna Med*. Vol 3 No 2 2019; 31-40. DOI : 10.36216/jpd.v3i2.73
- Cartier V., Aubé, C. 2014. Diagnosis of hepatocellular carcinoma. *Diagnostic and Interventional Imaging*. <http://dx.doi.org/10.1016/j.diii.2014.06.004>
- Ceniccola, G.D., Castro, M.G., Piovacari, S.M.F., Horie, L.M., Correa, F.G., Barrere, A.P.N. 2018. Current technologies in body composition assessment: advantages and disadvantages. *Nutrition*. 2018. doi: <https://doi.org/10.1016/j.nut.2018.11.028>
- Chang, K., Chen, J.D., Wu, W.T., Huang, K.C., Hsu, C.T., Han, D.S. 2018. Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. *Liver Cancer*. 2018;7:90–103. DOI: 10.1159/000484950
- Chen, L.K., Liu, L.K., Woo, J., Assantachai, P., Auyeung, T.W., Bahyah, K.S., *et al.* 2014. Sarcopenia in Asia : Consensus Report of the Asian Working Group for Sarcopenia. *Journal of the American Medical Director Association*. <http://dx.doi.org/10.1016/j.jamda.2013.11.025>
- Cheng, A.L., Amarapurkar, D., Chao, Y., Chen, P., Geschwind, J., Goh, K.L., *et al.* 2014. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an

International Expert Panel. *Liver International*. 2014; 34: 174–183.
DOI:10.1111/li.v.12314

Cheng, T.Y., Lee, P.C., Chen, Y.T., Chao, Y., Hou, M.-C., Huang, Y.H. 2020. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure. *Scientific Reports*, 10(1). doi:10.1038/s41598-020-75198-z (<https://doi.org/10.1038/s41598-020-75198-z>)

Choi, J.Y., Lee, J.M., Sirlin, C.B. 2014a. CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part I. Development, Growth, and Spread: Key Pathologic and Imaging Aspects. *Radiology*. 2014; 272:635–654. DOI : 10.1148/radiol.14132361

Choi, J.Y., Lee, J.M., Sirlin, C.B. 2014b. CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma. Part II. Extracellular Agents, Hepatobiliary Agents, and Ancillary Imaging Features. *Radiology*. 2014; 273:30–50. DOI: 10.1148/radiol.14132362

Christensen, J. F., Jones, L. W., Andersen, J. L., Daugaard, G., Rorth, M., Hojman, P. 2014. review Muscle dysfunction in cancer patients. *Annals of Oncology*. <http://doi.org/10.1093/annonc/mdt551>

Cunha G.M., Chernyak, V., Fowler, K.J., Sirlin, C.B. 2021. Up-to-Date Role of CT/MRI LI-RADS in Hepatocellular Carcinoma. *Journal of Hepatocellular Carcinoma*. 2021;8:513-527. <https://doi.org/10.2147/JHC.S268288>

Dahlan, M.S. 2009. Statistik untuk Kedokteran dan Kesehatan : Deskriptif, Bivariat dan Multivariat Dilengkapi Aplikasi dengan Menggunakan SPSS. Jakarta, Salemba Medika. Jilid I hal 157.

Dodson, R.M., Firoozmand, A., Hyder, O., Tacher, V., Cosgrove, D.P., Bhagat, N., et al. 2013. Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies. *Journal of Gastrointestinal Surgery*. (2013) 17:2123–2132. DOI 10.1007/s11605-013-2348-5

Durand, F., Buyse, S., Francoz, C., Laouénan, C., Bruno, O., Belghiti, J., et al. 2014. Prognostic value of muscle atrophy in cirrhosis using psoas muscle thickness on computed tomography. *Journal of Hepatology*. 2014 vol. 60 j 1151–1157. <http://dx.doi.org/10.1016/j.jhep.2014.02.026>

Ellis, H. 2011. Anatomy of the liver. *Surgery* : 29(12), pp. 589– 592. Elsevier Ltd. doi: 10.1016/j.mpsur.2011.09.012.

Fateen, W., Ryder, R.D. 2017. Screening for hepatocellular carcinoma: patient selection and perspectives. *Journal of Hepatocellular Carcinoma*. 2017:4 71–79. <http://dx.doi.org/10.2147/JHC.S105777>

Forner, A., Reig, M., Bruix, J. 2018. Hepatocellular carcinoma. *Lancet*. 2018; 391: 1301–14. [http://dx.doi.org/10.1016/S0140-6736\(18\)30010-2](http://dx.doi.org/10.1016/S0140-6736(18)30010-2)

- Fournier, L., Ammaria, S., Thiam, R., Cuénoda, C.A. 2014. Imaging criteria for assessing tumour response: RECIST, mRECIST, Cheson. *Diagnostic and Interventional Imaging*. (2014) 95, 689—703. <http://dx.doi.org/10.1016/j.diii.2014.05.002>
- Fujita, M., Takahashi, A., Hayashi, M., Okai, K., Abe, K., Ohira, H. 2019. Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma. *Hepatology Research*. 2019; 49: 778–786. doi: 10.1111/hepr.13331.
- Galle, P.R., Forner, A., Llovet, J.M., Mazzaferro, V., Piscaglia, F., Raoul, J.L., *et al*. 2018. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology*. 2018 vol. 69 j 182–236
- Golfieri, R., Cappelli, A., Cucchetti, A., Piscaglia, F., Carpenzano, M., Peri, E., *et al*. 2011. Efficacy of Selective Transarterial Chemoembolization in Inducing Tumor Necrosis in Small (< 5 cm) Hepatocellular Carcinomas. *Hepatology*. Vol. 53, No. 5, 2011. DOI :10.1002/hep.24246
- Gomez-Perez, S.L., Haus, J.M., Sheean, P., Patel, B., Mar, W., Chaudhry, V., *et al*. 2015. Measuring Abdominal Circumference and Skeletal Muscle From a Single Cross-Sectional Computed Tomography Image: A Step by Step Guide for Clinicians Using National Institutes of Health ImageJ. *American Society for Parenteral and Enteral Nutrition*. DOI: 10.1177/0148607115604149
- Gonzalez-Guindalini, F.D., Botelho, M.P.F., Harmath, C.B., Sandrasegaran, K., Miller, F.H., Salem, R., *et al*. 2013. Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging. *RadioGraphics*. 2013; 33:1781–1800. DOI : 10.1148/rg.336135511
- Goto, K., Suarez, A.A.R., Wensch, F., Baumert, T.F., Lupberger, J. 2020. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. *International Journal of Molecular Sciences*. 2020, 21, 3057; DOI:10.3390/ijms21093057
- Gu, D.H., Kim, M.Y., Seo, Y.S., Kim, S.G., Lee, H.A., Kim, T.H., *et al*. 2018. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. *Clinical and Molecular Hepatology*. 2018;24:319-330. <https://doi.org/10.3350/cmh.2017.0077>
- Guerrieri, F., Belloni, L., Pediconi, N., Levrero, M. 2013. Molecular Mechanisms of HBV-Associated Hepatocarcinogenesis. Article in *Seminars in Liver Disease* · May 2013. DOI: 10.1055/s-0033-1345721
- Hamaguchi, Y., Kaido, T., Okumura, S., Kobayashi, A., Hammad, A., Tamai, Y., *et al*. 2016. Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults. *Nutrition*. doi: 10.1016/j.nut.2016.04.003.

- Hamid, A.S., Tesfamariam, I.G., Zhang, Y., Zhang, Z.G. 2013. Afltoxin B1-induced hepatocellular carcinoma in developing countries: Geographical distribution, mechanism of action and prevention (Review). *Oncology Letters* 5: 1087-1092, 2013. DOI: 10.3892/ol.2013.1169.
- Hari, A., Berzigotti, A., Štabuc, B., Caglevič, N. 2019. Muscle psoas indices measured by ultrasound in cirrhosis—Preliminary evaluation of sarcopenia assessment and prediction of liver decompensation and mortality. *Digestive and Liver Diseases*. 2019, 51, 1502–1507, doi:10.1016/j.dld.2019.08.017.
- Harimoto, N., Shirabe, K., Yamashita, Y.I., Ikegami, T., Yoshizumi, T., Soejima, Y., *et al.* 2013. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. *British Journal of Surgery*. 2013; 100: 1523–1530. DOI: 10.1002/bjs.9258
- Hiraoka, A., Kumada, T., Michitaka, K., Toyoda, H., Tada, T., Ueki, *et al.* 2016. Usefulness of albumin-bilirubin (ALBI) grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. DOI: 10.1111/JGH_13250.AA
- Husodo, U. B. 2014. Kanker hati. In S. S. Ari W Sudoyo, Bambang Setiyohadi, Idrus Alwi (Ed.), *Buku Ajar ilmu Penyakit Dalam* jilid I edisi VI., Jakarta: Interna Publishing, pp. 3030–36
- Hyun, D., Shin, S.W., Cho, S.K., Park, K.B., Park, H.S., Choo, S.W., *et al.* 2014. Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. *Acta Radiologica*. 0(0) 1–9. DOI: 10.1177/0284185114560937
- Idée, J.M., Guiu, B. 2013. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. *Critical Reviews in Oncology/Hematology*. 88 (2013) 530–549. <http://dx.doi.org/10.1016/j.critrevonc.2013.07.003>
- Imai, K., Takai, K., Watanabe, S., Hanai, T., Suetsugu, A., Shiraki, M., *et al.* 2017. Sarcopenia Impairs Prognosis of Patients with Hepatocellular Carcinoma: The Role of Liver Functional Reserve and Tumor-Related Factors in Loss of Skeletal Muscle Volume. *Nutrients* : 9, 1054; doi:10.3390/nu9101054
- Kamachi, S., Mizuta, T., Otsuka, T., Nakashita, S., Ide Y., Miyoshi, K., *et al.* 2015. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. *Hepatology Research*. 2016; 46: 201–208. doi: 10.1111/hepr.12562
- Kim, T.N., Choi, K.M. 2013. Sarcopenia: Definition, Epidemiology, and Pathophysiology. *Journal of Bone Metabolism*. 2013;20:1-10. <http://dx.doi.org/10.11005/jbm.2013.20.1.1>

- Kim, H.Y., Jang, J.W. 2015. Sarcopenia in the prognosis of cirrhosis : Going beyond the MELD score. *World Journal of Gastroenterology*. 2015, 21(25), 7637–7647.
- Kobayashi, T., Kawai, H., Nakano, O., Abe, S., Kamimura, H., Sakamaki, A., *et al.* 2018. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intraarterial therapies. *BMC Cancer*. 2018, 18:756. <https://doi.org/10.1186/s12885-018-4673-2>
- Kohla, M.A.S., Zeid, M.I.A., Al-Warraky, M., Taha, H., Gish, R.G. 2015. Predictors of hepatic decompensation after TACE for hepatocellular carcinoma. *BMJ Open Gastroenterology*. 2015; 2:e000032. doi:10.1136/bmjgast-2015-000032
- Kulik, L., El-Serag, H.B. 2019. Epidemiology and Management of Hepatocellular Carcinoma. *Gastroenterology*. 2019;:-1 –15.
- Kwan, S.W., Fidelman, N., Ma, E., Kerlan, Jr. R.K., Yao, F.Y. 2012. Imaging Predictors of the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: A Radiological Pathological Correlation. *Liver Transplantation*. 18:727-736, 2012. DOI 10.1002/lt.23413
- Le, Y., Shen, J.X., Zhang, Y.F., He, M.K., Kan, A., Chen, H.L., *et al.* 2019. Transarterial Chemoembolization related to Good Survival for Selected Patients with advanced Hepatocellular Carcinoma. *Journal of Cancer*. 2019; 10(3): 665-671. doi: 10.7150/jca.28528
- Lee, C.M., Kang, B.K., Kim, M. 2021. Radiologic Definition of Sarcopenia in Chronic Liver Disease. *Life*. 2021, 11, 86. <https://doi.org/10.3390/life11020086>
- Lencioni, R. 2013. New Data Supporting Modified RECIST (mRECIST) for Hepatocellular Carcinoma. *Clinical Cancer Research*. 19(6) March 15, 2013. DOI: 10.1158/1078-0432.CCR-12-3796
- Llovet, J.M., Lencioni, R. 2020. mRECIST for HCC: Performance and novel refinements. *Journal of Hepatology*. 2020 vol. 72 j 288–306
- Llovet, J.M., Kelley, R.K., Villanueva, A., Singal, A.G., Pikarsky, E., Roayaie, S., *et al.* 2021. *Hepatocellular carcinoma*. <https://doi.org/10.1038/s41572-020-00240-3>
- Loffroy, R., Estivalet, L., Favelier, S., Pottecher, P., Genson, P.Y., Cercueil, J.P., *et al.* 2015. Interventional radiology therapies for liver cancer. *Hepatoma Research*. 2016;2:1-9. DOI: 10.4103/2394-5079.167439
- Loosen, S.H., Schulze-Hagen, M., Bruners, P., Tacke, F., Trautwein, C., Kuhl, C., *et al.* 2019. Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. *Cancers*. 2019, 11, 1503; doi:10.3390/cancers11101503

- Mardian, Y., Yano, Y., Ratnasari, N., Choridah, L., Wasityastuti, W., Setyawan, N.H., *et al.* 2019. Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study. *BMC Gastroenterology*. 2019, 19:229. <https://doi.org/10.1186/s12876-019-1152-4>
- Marrero, J.A., Kulik, L.M., Sirlin, C., Zhu, A.X., Finn, R.S., Abecassis, M.M., *et al.* 2018. Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*. doi: 10.1002/hep.29913
- Meza-Junco, J., Montano-Loza, A.J., Baracos, V.E., Prado, C.M.M., Bain, V.G., Beaumont, C., *et al.* 2013. Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma. *Journal of Clinical Gastroenterology*. 2013;47:861–870.
- Nishikawa, H., Shiraki, M., Hiramatsu, A., Moriya, K., Hino, K., Nishiguchi, S. 2016. JSH guidelines for sarcopenia in liver disease (first edition): Recommendation from the working group for creation of sarcopenia assessment criteria in the JSH. doi:10.1111/hepr.12774
- Nishino, M., Jagannathan, J.P., Ramaiya, N.H., den Abbeele, A.D. 2011. Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know. *American Journal of Roentgenology*, 195(August 2010), pp. 281–289. doi:10.2214/AJR.09.4110
- Pabst, R., 2011. Anatomy Atlas of Human Edited Volume 2 Lower Limb Trunk , Viscera., 15th ed. Elsevier Ltd, Munich.
- Prajapati, H.J., Spivey, J.R., Hanish, S.I., El-Rayes, B.F., Kauh, J.S., Chen, Z., *et al.* 2013. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). *Annals of oncology : official journal of the European Society for Medical Oncology*. 24(4), 965–973. <https://doi.org/10.1093/annonc/mds605>
- Piscaglia, Fabio., Ogasawara, S. 2018. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. *Liver Cancer*, 2018;7:104–119. DOI: 10.1159/000485471
- Rabouhans, J. S., Baron, A., Cazejust, J., Rosmorduc, O., Menu, Y. 2011. A radiologist's guide to the modified Response Evaluation Criteria in Solid Tumours (mRECIST) assessment of therapy for hepatocellular carcinoma', European Society of Radiology. Electronic Presentation Online System, Poster C-2, pp. 1–42. doi: 10.1594/ecr2011/C-2120.
- Reeves, H.L., Zaki, M.Y.W., Day, C.P. 2016. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD. *Digestive Diseases and Science*. 2016, 61:1234–1245. DOI 10.1 007/s10620-016-4085-6

- Santillan, C. 2020. CT and MRI of the liver for hepatocellular carcinoma. *Hepatoma Research*. 2020;6:63.<http://dx.doi.org/10.20517/2394-5079.2020.60>
- Sastroasmoro, S., Ismael, S. 2011. Usulan Penelitian. Dasar-dasar Metodologi Penelitian Klinis. Jakarta: Sagung Seto, pp. 31 –63.
- Sato, Y., Watanabe, H., Sone, M., Onaya, H., Sakamoto, N., Osuga, K., *et al.* 2013. Tumor response evaluation criteria for HCC treated using TACE: RECIST version 1.1 and mRECIST. *Upsala Journal of Medical Sciences*. 2013; 118: 16–22 . DOI: 10.3109/03009734.2012.729104
- Shibata, M., Nakajima, K., Higuchi, R., Iwane, T, Sugiyama, M, Nakamura, T. 2019. High Concentration of Serum Aspartate Aminotransferase in Older Underweight People: Results of the Kanagawa Investigation of the Total Check-Up Data from the National Database-2 (KITCHEN-2). *J Clin Med*. Aug 22;8(9):1282. doi: 10.3390/jcm8091282. PMID: 31443545; PMCID: PMC6780907.
- Shim , J.H., Lee, H.C., Kim, S.O., Shin, Y.M., Kim, K.M., Lim, Y.S., *et al.* 2012. Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization ?. A Validation Study of Old and New Models. *Radiology*. 2012; 262:708–718. DOI : 10.1148/radiol.11110282
- Sibulesky, L. 2013. Normal Liver Anatomy. *Clinical Liver Disease*, Vol 2, No. S1, March 2013. Doi : 10.1..2/cld.124.
- Sieghart, W., Huckle, F., Radosavljevic, M.P. 2015. Transarterial chemoembolization : Modalities, indication, and patient selection. *Journal of Hepatology*, 2015 vol. 62 j 1187–1195.
- Siregar, G.A. 2011. Penatalaksanaan non bedah dari karsinoma hati. *Universa Medicina*. Vol.24 No.1. pp35-42.
- Taniai, M. 2020. Alcohol and hepatocarcinogenesis. *Clinical and Molecular Hepatology*. 2020;26:736-741. <https://doi.org/10.3350/cmh.2020.0203>.
- Tarocchi, M., Polvani, S., Marroncini, G., Galli, A. 2014. Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. *World Journal of Gastroenterology*. 2014, September 7; 20(33): 11630-11640
- Trefts, E., Gannon, M., Wasserman, D.H. 2017. The Liver. *Current Biology*. 2017 November 06; 27(21): R1147–R1151. doi:10.1016/j.cub.2017.09.019.
- Villanueva, A. 2019. Hepatocellular Carcinoma. *The New England Journal of Medicine*. 2019;380:1450-62. DOI: 10.1056/NEJMra1713263
- White, J.A., Redden, D.T., Bryant, M.K., Dorn, D., Saddekni, S., Aal, A.K.A., *et al.* 2014. Predictors of repeat transarterial chemoembolization in the

treatment of hepatocellular carcinoma. *International Hepato-Pancreato-Biliary Association*. DOI:10.1111/hpb.12313

- Yamashima, M., Miyaaki, H., Honda, T., Shibata, H., Miuma, S., Taura, N., *et al.* 2017. Significance of psoas muscle thickness as an indicator of muscle atrophy in patients with hepatocellular carcinoma treated with sorafenib. *Molecular and Clinical Oncology*. 7: 449-453, 2017. doi: 10.3892/mco.2017.1321.
- Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A., Roberts, L.R. 2019. A global view of hepatocellular carcinoma: trends, risk, prevention and management. *Nature reviews. Gastroenterology & Hepatology*. <https://doi.org/10.1038/s41575-019-0186-y>
- Yi, S.W., Choi, J-S., Yi, J.J., Lee, Y.H., Han, K.J. 2018. Risk Factors for Hepatocellular Carcinoma by Age, Sex, and Liver Disorder Status : A Prospective Cohort Study in Korea. *Cancer*. July 1, 2018. DOI:10.1002/cncr.31406.
- Yuri, Y., Nishikawa, H., Enomoto, H., Ishii, A., Iwata, Y., Miyamoto, Y., *et al.* 2017. Implication of psoas muscle index on survival for hepatocellular carcinoma undergoing radiofrequency ablation therapy. *Journal of Cancer*. 2017; 8(9): 1507-1516. doi: 10.7150/jca.19175
- Zheng, B., Zhu, Y.J., Wang, H.Y., Chen, L. 2017. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. *Science China Life Sciences*. doi: 10.1007/s11427-016-9043-9
- Zhu, R. X., Seto, W., Lai, C., Yuen, M. 2016. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. *Gut and Liver*, Vol. 10, No. 3, May 2016, pp. 332-339. <http://dx.doi.org/10.5009/gnl15257>